Story
UBS Initiates Medtech Coverage, Taps Intuitive Surgical and Enovis as Buys
Summary
UBS launched coverage on several U.S. medical technology firms, issuing Buy ratings for Intuitive Surgical and Enovis on strong growth prospects, while assigning a Sell rating to Inspire Medical due to competitive and reimbursement challenges.
UBS initiated coverage on a group of U.S. medical technology companies on Monday, issuing favorable Buy ratings for robotic surgery leader Intuitive Surgical and orthopedic device maker Enovis. The firm took a more cautious or negative stance on others in the sector, highlighting a selective approach based on innovation and market expansion.
Bullish on Robotics and Orthopedics
In a note to clients, UBS stated that while the medtech sector offers opportunities from procedure growth and innovation, investors should be selective. The firm's most positive outlook was on Intuitive Surgical (ISRG), which it started with a Buy rating and a $500 price target.
UBS analysts believe investor concerns over automation risks and market saturation are overstated. The firm argued automation could accelerate the adoption of robotic surgery and projected a five-year revenue compound annual growth rate (CAGR) of about 15% for the company, citing opportunities in cardiac and endoluminal procedures.
Enovis (ENOV) also received a Buy rating with a $51 price target. UBS pointed to improving fundamentals following the integration of LimaCorporate, with management now shifting focus to organic growth. The firm highlighted new product launches and its ARVIS augmented reality platform, which it sees as a potential lower-cost alternative to full robotic systems.
AdCautious Outlook on Inspire and Integra
Conversely, UBS initiated coverage of Inspire Medical Systems (INSP) with a Sell rating and a $39 price target. According to the note, the company's slowing growth reflects "deeper structural challenges," including rising competition and uncertainty around reimbursement for its obstructive sleep apnea therapy. UBS believes consensus sales forecasts for the company are "too optimistic."
Integra LifeSciences (IART) received a Neutral rating and a $19 price target. While UBS acknowledged the company's leadership in neurosurgery and wound care, it concluded that the shares already reflect a stable growth trajectory. The firm sees "limited near-term catalysts" to drive a significant re-rating of the stock.
Read next
More on Stocks
Divergence in China: Consumer Stocks Hit Decade Low as Capital Flows to AI
Chinese consumer-focused stocks have fallen to their lowest levels in nearly ten years, pressured by weak domestic spending and a significant shift in investor capital toward the booming artificial intelligence sector.
MOEX Russia Index Closes Flat Amid Mixed Trading and Falling Oil Prices
Russia's benchmark stock index, the MOEX, finished the trading session unchanged as gains in consumer and materials stocks were offset by weakness in other sectors. The flat close came despite a drop in global oil prices and a strengthening of the Russian ruble.
Boeing 737 MAX Software Glitch Affects Autopilot, Prompts FAA Review
Boeing has identified a software flaw in its 737 MAX jets that can disable some automated navigation functions during certain landing scenarios, according to a Wall Street Journal report. The issue has prompted an FAA investigation and requests from major U.S. airlines to halt deliveries of aircraft with the new software.
Trump Announces New Fuel Economy Rules to End Biden-Era EV Push
Former President Donald Trump stated he has approved new fuel economy standards designed to reverse the Biden administration's policies that encouraged electric vehicle production. The move, announced on social media, signals a major shift in U.S. automotive regulatory policy.